Equity Profile

RYTM

Rhythm Pharmaceuticals, Inc.

Health CareBiotechnology$8.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare genetic disorders related to obesity....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and performance.

$-0.83

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$68M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RYTM Q2-2026 Earnings Preview

Context

Company Snapshot

Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare genetic disorders related to obesity. With a market cap of $8 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs in metabolic diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-1.49%

Avg Stock Reaction

+1.37%

Last Quarter Recap

In Q1-2026, Rhythm Pharmaceuticals reported an EPS of $-0.83, slightly beating analyst expectations. The stock reacted positively, gaining 7.86% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Rhythm Pharmaceuticals to report a loss of $-0.83 per share on revenue of $68 million for Q2-2026. The market is closely watching these figures to gauge the company's growth trajectory.

Bull Case

If the company can exceed revenue expectations and show signs of improving profitability, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could negatively impact investor sentiment and the stock price.

Key Metrics to Watch

EPS

$-0.83

Earnings per share is a key indicator of the company's profitability and performance.

Revenue

$68M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Rhythm Pharmaceuticals achieve revenue of at least $68 million this quarter?

Meeting or exceeding this revenue target will be crucial for demonstrating growth and market demand for their products.

What specific plans does management have to improve EPS moving forward?

Investors will be keen to hear about strategies that could lead to reduced losses and a path toward profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth due to recent advancements in their product pipeline that have not been fully factored in.

Supporting Evidence

Recent positive trends in patient enrollment for clinical trials suggest stronger future sales.

The options market is pricing in a larger move than historical averages, indicating potential for a significant surprise.

The company's recent partnerships could lead to increased market penetration that analysts have not fully accounted for.

Key Risk

If revenue exceeds $72 million, it could challenge the current bearish sentiment and shift market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reveal whether the company can sustain its growth trajectory and improve its financial health.

Bull Confirmed If

A revenue figure above $72 million would confirm the bull case and indicate strong market demand.

Bear Confirmed If

If revenue falls below $64 million, it would support the bear case and raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±11.61%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±11.6% while RYTM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.6%

Calls (900)P/C Ratio: 0.44Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Rhythm beats expectations and raises guidance, history suggests the stock could rise by around 3.24% on the first day.

In-Line / Cautious

If the results are in line with expectations but management is cautious, the stock may see a muted reaction.

Miss

Should the company miss on EPS or revenue, history suggests a potential decline of about 0.50% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on patient enrollment in clinical trials.
2Management's commentary on market demand for their products.
3Details on cost management strategies to improve EPS.
4Insights into partnerships or collaborations that could enhance growth.
5Any changes to guidance for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare genetic disorders related to obesity....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and performance.

$-0.83

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$68M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RYTM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-1.49%

Avg Stock Reaction

+1.37%

Last Quarter Recap

In Q1-2026, Rhythm Pharmaceuticals reported an EPS of $-0.83, slightly beating analyst expectations. The stock reacted positively, gaining 7.86% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company can exceed revenue expectations and show signs of improving profitability, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could negatively impact investor sentiment and the stock price.

Key Metrics to Watch

EPS

$-0.83

Earnings per share is a key indicator of the company's profitability and performance.

Revenue

$68M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Rhythm Pharmaceuticals achieve revenue of at least $68 million this quarter?

Meeting or exceeding this revenue target will be crucial for demonstrating growth and market demand for their products.

What specific plans does management have to improve EPS moving forward?

Investors will be keen to hear about strategies that could lead to reduced losses and a path toward profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth due to recent advancements in their product pipeline that have not been fully factored in.

Supporting Evidence

Recent positive trends in patient enrollment for clinical trials suggest stronger future sales.

The options market is pricing in a larger move than historical averages, indicating potential for a significant surprise.

The company's recent partnerships could lead to increased market penetration that analysts have not fully accounted for.

Key Risk

If revenue exceeds $72 million, it could challenge the current bearish sentiment and shift market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reveal whether the company can sustain its growth trajectory and improve its financial health.

Bull Confirmed If

A revenue figure above $72 million would confirm the bull case and indicate strong market demand.

Bear Confirmed If

If revenue falls below $64 million, it would support the bear case and raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±11.61%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±11.6% while RYTM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.6%

Calls (900)P/C Ratio: 0.44Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Rhythm beats expectations and raises guidance, history suggests the stock could rise by around 3.24% on the first day.

In-Line / Cautious

If the results are in line with expectations but management is cautious, the stock may see a muted reaction.

Miss

Should the company miss on EPS or revenue, history suggests a potential decline of about 0.50% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on patient enrollment in clinical trials.
2Management's commentary on market demand for their products.
3Details on cost management strategies to improve EPS.
4Insights into partnerships or collaborations that could enhance growth.
5Any changes to guidance for the upcoming quarters.